We gratefully thank the Fondation des Maladies du Coeur and the Fondation de l'Hôpital du Saint-Sacrement for financial support; Dr. C. Matthews (University of Guelph) for helpful discussions concerning the in vivo studies; N. Marceau and A. Grimaud for generously providing antibodies for vimentin and elastin; R. Guidouin and S. Bourassa from the Institut des Biomatériaux de Québec for SEM; K. Baker, L. Martin, A. Pusterla, and L. Vue for technical assistance; C. Marin for photographic assistance; and M. Michel and F. Berthod for careful review of the manuscript. L. Germain and F. A. Auger were recipients of Scholarships from the Fonds de la Recherche en Santé du Québec and N. L'Heureux was recipient of Studentships from the Fonds FCAR du Québec.
1 Current address: Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093-0412, USA. E-mail: .
1 Correspondence: Laboratoire d'Angiogénèse Expérimentale/LOEX, Hôpital du Saint-Sacrement, 1050, chemin Sainte-Foy, Québec (Québec) G1S 4L8, Canada. E-mail: firstname.lastname@example.org .
3 Abbreviations: TEBV, tissue-engineered blood vessel (or vessels); SMC, smooth muscle cell (or cells); EC, endothelial cell; FBS, fetal bovine serum; ac-LDL, acetylated low density lipoproteins; IM, inner membrane (or membranes); CMFDA, 5-chloromethylfluorescein-diacetate; DiI, 1;1'-dioctadecyl-3;3;3';3'-tetramethylindocarbocyanine chlorate; HSV, human saphenous veins; PGI2, prostacyclin; SEM, scanning electron microscopy; MMP, matrix metalloproteinase; ECM, extracellular matrix; MHC, major histocompatibility complex.
Received for publication June 27, 1997. Accepted for publication October 2, 1997.